Skip to main content

Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study


Sixty-four patients with non metastatic high risk breast cancer were randomized in a double blind trial of adjuvant immunotherapy with sodium ditiocarb (DDC) versus placebo. All patients underwent prior surgery (mammectomy according to Patey) then adjuvant FAC chemotherapy +/- DDC. With a median follow-up of 5 years we observed 6 relapses and 5 deaths in DDC group; 13 relapses and 12 deaths in control group. At 6 years, overall survival is 81% in DDC group versus 55%. Disease free survival (DFS) is 76% in DDC group versus 55%. DDC associated to chemotherapy and locoregional treatment can improve survival and probably DFS in this high risk breast cancer subgroup.

This is a preview of subscription content, access via your institution.



sodium ditiocarb


disease free survival


overall survival




5 Fluorouracil, Adrianycin, Cyclopho-pharmide


  1. Early breast cancer trialists' collaborative group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 71–85.

    Google Scholar 

  2. Mathe G, Amiel J-L, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, de Vassal F. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969; 1; 697.

    PubMed  Google Scholar 

  3. Smith GV, Morese PA, Deraps GD, Raju S, Hardy JD Immunotherapy of patients with cancer. Surgery 1973; 74: 59–68.

    PubMed  Google Scholar 

  4. Renoux G, Renoux M Thymus-like activities of sulphur derivatives on T-cell differentiation. J Exp Med, 1977, 145, 466–471.

    PubMed  Google Scholar 

  5. Perchellet J-P, Abney NL, Thomas RM, Perchellet EM, Maatta EA: Inhibition of multistage tumor promotion in mouse skin by-diethyldithiocarbamate. Cancer Res, 1987, 6302–6309.

  6. Kumar KS, Sancho AM, Weiss JF: A novel interaction of diethyldithiocarbamate with the glutathione/glutathione peroxydase system. Int J Rad Oncol, 1986, 12, 1463–1467.

    Google Scholar 

  7. Rojas AF, Mickiewicz E, Feierstein JN, Glait H, Olivari AJ: Levamisole in advanced human breast cancer. Lancet, 1976, 1, 212–215.

    Google Scholar 

  8. Klefström P, Nuortio L. Levamisole in the treatment of advanced breast cancer. Act Oncol, 1991, 30, 347–352.

    Google Scholar 

  9. Treurniet-Donker AD, Meischke-de Jong ML, van Putten WLJ: Levamisole as adjuvant immunotherapy in breast cancer. Cancer, 1987, 59, 1590–1593.

    PubMed  Google Scholar 

  10. Betzler M, Schreml W, Lang M, Lohrmann HP, Flad HD, Schlag P, Herfarth C, Hiempel H: Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up. Recent Results Cancer Res, 1982, 80, 185–191.

    PubMed  Google Scholar 

  11. Executive Committee of the Danish Breast Cancer Cooperative Group: Increased breast-cancer recurrence rate after adjuvant therapy with levamisole. Lancet, 1980, 2, 824–827.

    Google Scholar 

  12. Giuliano AE, Sparks FC, Patterson K, Spears I, Morton DL: Adjuvant chemo-immunotherapy in stage II carcinoma of the breast. J Surg Oncol, 1986, 31, 255–259.

    PubMed  Google Scholar 

  13. Hubay CA, Pearson OH, Manni A, Gordon NH, McGuire WL: Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result. J Steroid Biochem, 1985, 23, 1147–1150.

    PubMed  Google Scholar 

  14. Gutterman JU, Cardenas JO, Blumenschein GR, Hortobagyi G, Burgess MA, Livingston RB, Mavligit GM, Freireich EJ, Gottlieb JA, Hersch EM: Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Brit Med J, 1976, 2, 1222–1225.

    PubMed  Google Scholar 

  15. Lacour J, Lacour F, Ducot B, Spirer A, Michelson M, Petit JY, Sarrazin D, Contesso G: Polyadenylic-polyuridilic acid as adjuvant in the treatment of operable breast cancer: recent results. Eur J Surg Oncol, 1988, 14, 311–316.

    PubMed  Google Scholar 

  16. Lang J-M, Touraine J-L, Trepo C & AIDS-Imuthiol french study group: Randomised, double-blind, placebo-controlled trial of ditiocarbsodium (“Imuthiol”) in human immunodeficiency virus infection. Lancet, 1988, 2, 702–705.

    PubMed  Google Scholar 

  17. Hersh EM, Brewton G, Aabrams D, Bartlett J, Galpin J, Gill P, Gorter R, Gottlieb M, Jonikas JJ, Landesman S, Levine A, Marcel A, Petersen EA, Whitside M, Zahradnik J, Negron C, Boutitie F, Caraux J, Dupuy J-M, Salmi LR: Ditiocarb sodium therapy in patients with symptomatic HIV infection and AIDS. JAMA, 1991, 265, 1538–1544.

    PubMed  Google Scholar 

  18. Lin PS, Kwock L, Goodchild NT. Copper chelator enhancement of bleomycin cytotoxicity. Cancer, 1980, 48, 2360–2364.

    Google Scholar 

  19. Borch RF, Pleasants ME Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. Proc Natl Acad Sci, 1979, 76, 6611–6614.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dufour, P., Lang, J.M., Giron, C. et al. Sodium ditiocarb as adjuvant immunotherapy for high risk breast cancer: A randomized study. Biotherapy 6, 9–12 (1993).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

Key words

  • adjuvant immunotherapy
  • breast cancer
  • ditiocarb sodium